Literature DB >> 11375353

Requirement for p38 and p44/p42 mitogen-activated protein kinases in RAGE-mediated nuclear factor-kappaB transcriptional activation and cytokine secretion.

C H Yeh1, L Sturgis, J Haidacher, X N Zhang, S J Sherwood, R J Bjercke, O Juhasz, M T Crow, R G Tilton, L Denner.   

Abstract

Advanced glycation end product (AGE) activation of the signal-transducing receptor for AGE (RAGE) has been linked to a proinflammatory phenotypic change within cells. However, the precise intracellular signaling pathways involved have not been elucidated. We demonstrate here that human serum albumin modified with N(epsilon)-(carboxymethyl)lysine (CML), a major AGE adduct that progressively accumulates with aging, diabetes, and renal failure, induced nuclear factor (NF)-kappaB-driven reporter gene expression in human monocytic THP-1 cells. The NF-kappaB response was blocked with a synthetic peptide corresponding to the putative ligand-binding domain of RAGE, with anti-RAGE antiserum, and by coexpression of truncated receptors lacking the intracellular domain. Signal transduction from RAGE to NF-kappaB involved the generation of reactive oxygen species, since reporter gene expression was blocked with the antioxidant N-acetyl-L-cysteine. CML-modified albumin produced rapid transient activation of tyrosine phosphorylation, extracellular signal-regulated kinase 1 and 2, and p38 mitogen-activated protein kinase (MAPK), but not c-Jun NH(2)-terminal kinase. RAGE-mediated NF-kappaB activation was suppressed by the selective p38 MAPK inhibitor SB203580 and by coexpression of a kinase-dead p38 dominant-negative mutant. Activation of NF-kappaB by CML-modified albumin increased secretion of proinflammatory cytokines (tumor necrosis factor-alpha, interleukin-1beta, and monocyte chemoattractant protein-1) severalfold, and inhibition of p38 MAPK blocked these increases. These results indicate that p38 MAPK activation mediates RAGE-induced NF-kappaB-dependent secretion of proinflammatory cytokines and suggest that accelerated inflammation may be a consequence of cellular activation induced by this receptor.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11375353     DOI: 10.2337/diabetes.50.6.1495

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  83 in total

1.  Advanced glycation endproduct (AGE) receptor 1 is a negative regulator of the inflammatory response to AGE in mesangial cells.

Authors:  Changyong Lu; John Cijiang He; Weijing Cai; Huixian Liu; Li Zhu; Helen Vlassara
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-02       Impact factor: 11.205

2.  Advanced glycation end products induce tubular epithelial-myofibroblast transition through the RAGE-ERK1/2 MAP kinase signaling pathway.

Authors:  Jin H Li; Wansheng Wang; Xiao R Huang; Matthew Oldfield; Ann M Schmidt; Mark E Cooper; Hui Y Lan
Journal:  Am J Pathol       Date:  2004-04       Impact factor: 4.307

Review 3.  Trends in advanced glycation end products research in diabetes mellitus and its complications.

Authors:  José D Méndez; Jianling Xie; Montserrat Aguilar-Hernández; Verna Méndez-Valenzuela
Journal:  Mol Cell Biochem       Date:  2010-03-23       Impact factor: 3.396

4.  Homodimerization is essential for the receptor for advanced glycation end products (RAGE)-mediated signal transduction.

Authors:  Hongliang Zong; Angelina Madden; Micheal Ward; Mark H Mooney; Christopher T Elliott; Alan W Stitt
Journal:  J Biol Chem       Date:  2010-05-26       Impact factor: 5.157

5.  Advanced glycation end product (AGE)-receptor for AGE (RAGE) signaling and up-regulation of Egr-1 in hypoxic macrophages.

Authors:  Yunlu Xu; Fatouma Toure; Wu Qu; Lili Lin; Fei Song; Xiaoping Shen; Rosa Rosario; Joel Garcia; Ann Marie Schmidt; Shi-Fang Yan
Journal:  J Biol Chem       Date:  2010-05-27       Impact factor: 5.157

6.  MK615 decreases RAGE expression and inhibits TAGE-induced proliferation in hepatocellular carcinoma cells.

Authors:  Yuhki Sakuraoka; Tokihiko Sawada; Toshie Okada; Takayuki Shiraki; Yoshikazu Miura; Katsuya Hiraishi; Tatsushi Ohsawa; Masakazu Adachi; Jun-ichi Takino; Masayoshi Takeuchi; Keiichi Kubota
Journal:  World J Gastroenterol       Date:  2010-11-14       Impact factor: 5.742

7.  Advanced glycation end products, aortic stiffness, and wave reflection in peritoneal dialysis as compared to hemodialysis.

Authors:  Fabrice Mac-Way; Véronique Couture; Mihai S Utescu; Sophie Ignace; Sacha A De Serres; Renée-Claude Loignon; Karine Marquis; Richard Larivière; Mohsen Agharazii
Journal:  Int Urol Nephrol       Date:  2013-11-17       Impact factor: 2.370

8.  Targeting of RAGE-ligand signaling impairs breast cancer cell invasion and metastasis.

Authors:  T Kwak; K Drews-Elger; A Ergonul; P C Miller; A Braley; G H Hwang; D Zhao; A Besser; Y Yamamoto; H Yamamoto; D El-Ashry; J M Slingerland; M E Lippman; B I Hudson
Journal:  Oncogene       Date:  2016-09-26       Impact factor: 9.867

9.  Expression of S100A12 (EN-RAGE) in cystic fibrosis.

Authors:  D Foell; S Seeliger; T Vogl; H-G Koch; H Maschek; E Harms; C Sorg; J Roth
Journal:  Thorax       Date:  2003-07       Impact factor: 9.139

Review 10.  Muller glia in retinal innate immunity: a perspective on their roles in endophthalmitis.

Authors:  Ashok Kumar; Rajeev K Pandey; Lindsay J Miller; Pawan K Singh; Mamta Kanwar
Journal:  Crit Rev Immunol       Date:  2013       Impact factor: 2.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.